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Abstract 
Background. Circulating Angiotensin Converting Enzyme 2 (ACE2) activity is increased in 
patients with cardiovascular (CV) disease, but there is little information about changes in ACE2 
in chronic kidney disease (CKD) patients without history of cardiovascular disease. We 
examined circulating ACE2 activity in CKD patients stages 3-5 (CKD3-5) and dialysis (CKD5D) 
without any history of CV disease.  
Methods. Circulating ACE2 activity was measured in human EDTA plasma samples from the 
NEFRONA study (n=2572): control group (CONT) (n=568), CKD3-5 (n=1458) and CKD5D 
(n=546). Different clinical and analytical variables such as gender, age; history of diabetes 
mellitus (DM), dyslipidemia, hypertension; glycemic, renal, lipid and anemia profiles; vitamin D 
analogues treatment and antihypertensive treatments (ACEi and ARBs) were analyzed. 
Circulating ACE2 and ACE activities were measured using modified fluorimetric assay for 
EDTA-plasma samples, where zinc chloride was added to recover enzymatic activity. 
Results. In CKD3-5 and CKD5D circulating ACE2 activity was significantly decreased as 
compared to CONT, but no differences were found between CKD3-5 and CKD5 when 
performing paired case-control studies. By multivariate linear regression analysis male gender 
and advanced age were identified as independent predictors of ACE2 activity in all groups. 
Diabetes was identified as independent predictor of ACE2 activity in CKD3-5. Circulating ACE 
activity was significantly increased in CKD3-5 and CKD5D as compared to CONT, and in 
CKD5D as compared to CKD3-5. By multiple regression analysis, female gender and younger 
age were identified as independent predictors of ACE activity in CONT and CKD3-5. Diabetes 
was also identified as an independent predictor of ACE activity in CKD3-5 patients. 
Conclusions. Circulating ACE2 and ACE activity can be measured in human EDTA plasma 
samples with zinc added to recover enzymatic activity. In a CKD population without previous 
history of CV disease, ACE2 activity from human EDTA plasma samples directly correlated with 
the classical CV risk factors namely older age, diabetes and male gender. Our data suggest that 
circulating ACE2 is altered in CKD patients at risk for CV event. 
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Short summary 
Circulating ACE2 and ACE activity can be measured in human EDTA plasma samples with zinc 
added to recover enzymatic activity. In a CKD population without previous history of CV 
disease, ACE2 activity correlates with the classical CV risk factors namely older age, diabetes 
and male gender, suggesting that ACE2 could have therapeutic implications for CV disease in 
CKD patients. 
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Introduction 
Patients with chronic kidney disease (CKD) have an increased cardiovascular (CV) risk that 
accounts for more than 50% of the overall mortality [1]. Previous studies have found an 
independent association between lower levels of the estimated glomerular filtration rate (GFR) 
and the risk of CV disease (death, CV events and hospitalization). This risk is evident at an 
estimated GFR<60mL/min/1.73m2, and increases with an estimated GFR<45mL/min/1.73m2 [2]. 
The mechanisms that contribute to the pathogenesis of CV disease in CKD are complex, and 
include both traditional and non-traditional CV risk factors [3]. Nonetheless, it is well known that 
enhanced activation of the renin-angiotensin system (RAS), among others, plays a major role in 
the progression of cardiac and renal injury [4].  
Within the RAS, the Angiotensin-Converting Enzyme (ACE) [5] converts Angiotensin(Ang) I into 
the vasoconstrictor AngII, which mediates its effects predominantly through angiotensin type 1 
receptor and is responsible for the pathophysiological effects of the RAS. AngII increases blood 
pressure and contributes to cardiac remodeling, fibrosis, inflammation, thrombosis and plaque 
rupture [6]. In 2000, ACE2, an enzyme that cleaves the C-terminal amino acid of AngII to 
generate the peptide Ang1-7 was identified [7]. Ang1-7 acts via the Mas receptor to counteract 
the adverse effects of AngII [8]. Previous experimental studies have reported that 
downregulation of ACE2 leads to age-dependent development of glomerular mesangial 
expansion, accelerated progression of glomerulosclerosis, tubular injury, macrophage infiltration 
and interstitial fibrosis [9-11]. 
ACE2 is an integral cell membrane protein that can undergo cleavage or shedding to release 
the catalytically active ectodomain into the circulation. Initial studies in a large cohort were able 
to detect circulating ACE2 activity in only 7.5% of the subjects and it was~100-fold lower than 
ACE [12]. Interestingly, subjects with detectable ACE2 were older than those without and had a 
higher prevalence of CV disease, diabetes and hypertension suggesting that ACE2 may be 
upregulated in subjects with CV disease to counteract the adverse effect of AngII. Subsequent 
studies demonstrated that circulating ACE2 activity could also be detected in healthy subjects 
[13] and that soluble ACE2 activity is increased in heart failure patients, acute myocardial 
infarction[14], and correlates with the severity of the heart disease [15]. Circulating ACE2 levels 
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are increased in patients with type 1 diabetes and vascular complications [16]. Our group also 
demonstrated that circulating ACE2 activity can be measured in kidney transplant patients (KT), 
suggesting that it may be used as a non-invasive marker to understand the role of RAS in KT 
[17]. Recently, Roberts et al. showed that plasma ACE2 activity was lower in patients 
undergoing hemodialysis than in pre-dialysis patients with CKD [18]. However, circulating ACE2 
activity has not been studied in CKD patients without previous history of CV events. Therefore, 
the aim of this study was to determine the levels of circulating ACE2, ACE, and renin activities 
in CKD patients without any history of CV disease, and to determine the factors associated with 
circulating ACE2 and ACE activities in this population. 
Subjects and Methods 
Patients and Variables 
2572 subjects from an observational and multicenter study (NEFRONA project), recruited from 
October 2009 to June 2011, were studied [19, 20]. Male and female patients without history of 
CV disease (angina pectoris, acute myocardial infarction, ischemic stroke, hemorrhagic stroke, 
abdominal aortic aneurysm and atherosclerosis), and ages ranged between 18 and 74 years old 
were included in the study. Exclusion criteria were pregnancy, VIH infection, any type of 
transplant or history of transplant, previous history of carotid artery disease, patients with active 
infections and/or hospitalized in the last month, and intercurrent illness that presumes absence 
of follow-up or survival expectation less than 1year. 
Patients were classified into three groups according to their glomerular filtration rate (MDRD-4): 
1458 non-dialysis patients with CKD stages 3-5 (CKD3-5, MDRD-4<60ml/min/1.73m2); 546 
dialysis(hemodialysis or peritoneal dialysis) patients (CKD5D); and 568 subjects with MDRD-
4≥60ml/min/1.73m2 were used as controls (CONT). 
Clinical variables analyzed were gender, age, history of diabetes, hypertension, dyslipidemia, 
and smoking (active smokers over the last month). Angiotensin Converting Enzyme inhibitor 
(ACEi), Angiotensin Receptor Blockade (ARBs), diabetes medication (insulin and oral 
antidiabetic drugs), and vitamin D analogues treatments were recorded. Analytical variables 
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analyzed were: glycemic (blood glucose and glycosylated hemoglobin), lipid and anemia 
profiles. Presence of plaques was determined by ultrasound of the carotid arteries. 
EDTA-anticoagulated plasma samples were collected from all patients and controls, centrifuged 
at 3000g and then frozen at –80°C until analysis. The protocol has been reviewed and approved 
by the ethical review board of each hospital, and each participant signed an informed consent 
document before being included into the study. 
ACE2 Enzymatic Assay 
The ACE2 fluorescent enzymatic assay protocol was performed as previously described by our 
group, using an ACE2-quenched fluorescent substrate (Mca-Ala-Pro-Lys(Dnp)-OH, BioMol; 
Enzo, Life Sciences)[14, 17, 21]. Plasma samples were collected into tubes containing 
ethylenediamine-tetraacetic acid (EDTA), a chelating agent of loosely bound metal ions such as 
Zinc2+, which acts as a cofactor for carboxypeptidases. As EDTA inhibits ACE2 and ACE activity 
[22], zinc chloride(ZnCl2) was added to the plasma samples to avoid its bounding. Briefly, 2µl of 
plasma were incubated with buffer(100mM Tris-HCl, 600mM NaCl, 10µM ZnCl2, pH 7.5) in the 
presence of protease inhibitors(100µM captopril, 5µM amastatin, 5µM bestatin and 10µM Z-Pro-
prolinal) and in the presence of different concentrations of ZnCl2 (0, 0.5, 1 and 3mM) (Figure 
1A). Samples were incubated with 20µM of the quenched fluorescent substrate in reaction 
buffer (final volume 100µL) at 37ºC for 16hours. The optimal concentration of ZnCl2 for the 
determination of ACE2 activity was 0.5mM. ACE2 activity was also calculated in heparin-plasma 
and serum samples from 21 subjects as previously described [14,17].We performed a standard 
curve of the rhACE2 adding increasing quantities of rhACE2 (0, 1, 2, 4, 8 and 16ng) (Figure 1C). 
In a set of experiments, serum and EDTA-plasma samples were incubated with human 
recombinant ACE2 (Calbiochem) in presence or absence of ZnCl2. Experiments were carried 
out in duplicate and results were expressed as RFU/µL plasma/hour. 
ACE Enzymatic Assay 
The ACE fluorescent enzymatic assay was performed as previously described with 
modifications [23]. ZnCl2 was tested to find the optimal concentration for reversing the effect of 
EDTA. Briefly, 0.83µL of plasma with different concentrations of ZnCl2 (0, 7.81, 15.63 and 
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31.25mM) (Figure 1B) were incubated with 73µL of appropriate buffer (0.5M borate buffer and 
5.45M N-hippuryl-His-Leu (HHL)) at 37ºC for 25minutes. Finally, the fluorescent adduct of the 
enzyme-catalyzed product L-histidyl-L-leucine was quantified. A concentration of 15.63mM was 
found to be optimal for the detection of ACE. ACE activity was also calculated in heparin-
plasma and serum samples from 21 subjects as previously described [17]. Experiments were 
carried out in duplicate and results were expressed as RFU/µL plasma. 
Statistical Analysis 
Normality of the continuous variables was assessed by normal probability plots. Variables were 
expressed as mean±SE. Paired case-control studies were performed: CONT versus CKD3-5 
(280 pairs), CONT versus CKD5D (188 pairs) and CKD3-5 versus CKD5D (360 pairs), with an 
equal distribution of gender, diabetes, hypertension, dyslipidemia, smoking habits, weight(± 5 
kg) and age (± 3 years). Continuous variables were evaluated by the non-parametric Mann-
Whitney test. Bivariate correlations were calculated by the Spearman’s correlation coefficient. 
ANOVA was used among plasma ACE2 and ACE activity. The intraclass correlation coefficient 
(ICC) was used to determine the concordance of the assay between the different human 
samples. Multiple linear regression analyses, using the natural logarithmic transformation of 
plasma ACE2 and ACE activity, were carried out to identify independent predictors of enzymatic 
activity. SPSS version 18.0 for Windows was used for statistical calculations and R package 
version 3.0.2 was used for case-control studies. P<0.05 was considered statistically significant. 
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Results 
Patient characteristics 
In total, 2572 patients were included in the study. Circulating ACE2 and ACE activities were 
measured in 568 CONT subjects and 2004 CKD patients without previous history of 
cardiovascular disease, divided into those not requiring dialysis(CKD3-5) and those in 
dialysis(CKD5D). Characteristics of study subjects are shown in Table 1. CKD5D were younger 
and thinner than CKD3-5. CKD3-5 and CKD5D patients had higher prevalence of hypertension 
and dyslipidemia than CONT. NEFRONA is the first large study describing the actual 
prevalence of subclinical atheromatosis across different CKD stages. The baseline 
atherosclerosis parameters of the patients have been detailed by Arroyo D. et al. [24].  
ACE2 and ACE activities in EDTA-plasma samples 
We studied ACE and ACE2 activities in EDTA-plasma samples. For this purpose, ACE and 
ACE2 activities were measured in different conditions: EDTA-plasma samples, EDTA-plasma 
samples with added ZnCl2, serum samples and plasma samples collected on heparin from 21 
subjects 
We found a strong correlation with ICC (≥0.84) between the different studied samples (plasma 
on EDTA+ZnCl2, heparin and serum) for both ACE2 and ACE activities. In addition, we were 
able to recover ≥91% of ACE2 activity and ≥83% of ACE activity from EDTA-plasma when 
ZnCl2 was added to the assays (Table 2).  
In concordance with the non-detectable ACE2 activity observed in EDTA-plasma samples, 
when rhACE2 was added to the EDTA-plasma, ACE2 activity was not observed (Figure 1D). As 
expected, when ZnCl2
 was added to the EDTA-plasma with rhACE2, ACE2 activity was 
detected. These results, demonstrated that within EDTA-plasma neither endogenous or 
exogenous ACE2 activities were detected, however the addition of zinc to the reaction was able 
to recover the enzymatic activity.  
ACE2 activity 
Circulating ACE2 activity was significantly decreased in CKD3-5 as compared to CONT 
(45.4±1.12 versus 52.9±1.50, p<0.001) and in CKD5D as compared to CONT (38.5±1.62 versus 
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52.9±1.50, p<0.001). In addition, ACE2 was significantly decreased in CKD5D as compared to 
CKD3-5 (38.5±1.62 versus 45.4±1.12, p<0.001)(Figure 2A). However, when paired case-control 
studies were performed, no differences between CKD3-5 and CKD5D were found 
(p=0.27)(Figure 2B). Therefore, we analyzed all groups separately. 
ACE2 activity was significantly increased in males as compared to females in all studied groups 
(p<0.001). Furthermore, ACE2 activity was also increased in patients with plaques as compared 
to those without plaques (p<0.001)(Table 3). 
CONT and CKD3-5 with diabetes showed increased circulating ACE2 activity as compared to 
non-diabetic patients (p=0.003 and p<0.001). However, no differences were observed in dialysis 
patients (p=0.60). Hypertension was also associated with increased ACE2 activity in CONT 
(p<0.001)(Table 3). Patients with dyslipidemia showed increased levels of circulating ACE2 in 
CONT (p<0.001) and CKD5D (p=0.028), but no differences were found in CKD3-5 (p=0.53). 
Interestingly, circulating ACE2 activity was significantly increased in smoker as compared to 
non-smoker CKD3-5 (p=0.03)(Table 3). 
We found a significant direct correlation between ACE2, age and glycosylated hemoglobin in 
both CONT (p<0.001) and CKD3-5 (p<0.05). In addition, a direct correlation between ACE2 and 
age was found in CKD5D (p=0.038). 
Circulating ACE2 activity was significantly increased in CONT and CKD5D on ARBs therapy as 
compared to non-treated patients (p=0.002). Treatment with ACEi did not influence circulating 
ACE2 (Table 3). ACE2 activity was also increased in CONT (p=0.007) and CKD3-5 (p<0.001) 
under oral antidiabetic agents as compared to non-treated. In addition, insulin therapy increased 
ACE2 activity in CKD3-5 (p<0.001)(Table 3). Surprisingly, circulating ACE2 was decreased in 
CKD5D treated with cholecalciferol as compared to non-treated patients (p=0.027)(Table 3). 
By multivariate linear regression analysis (Table 4), male gender and advanced age were 
identified as independent predictors of circulating ACE2 activity in all studied groups. Diabetes 
was also identified as independent predictor of ACE2 activity in CKD3-5. In addition, ARBs and 
cholecalciferol therapies were independent predictors of ACE2 in CKD5D. 
ACE activity 
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Circulating ACE activity was significantly increased in CKD3-5 as compared to CONT 
(4181.65±58.37 versus 3809.13±71.96, p=0.035) and in CKD5D as compared to CONT 
(4454.48±87.10 versus 3809.13±71.96, p<0.001). In addition, ACE activity was significantly 
increased in CKD5D as compared to CKD3-5 (4454.48±87.10 versus 4181.65±58.37, p=0.001) 
(Figure 3A). In concordance, when paired case-control studies were performed, same results 
were observed (Figure 3B).  
Circulating ACE activity was increased in females as compared to males in CONT and CKD3-5 
(p<0.001). However, no differences were observed in CKD5D (p=0.057)(Table 3). 
CONT with presence of plaques showed decreased levels of circulating ACE activity as 
compared to those without plaques (p=0.011). However, no differences were observed in 
CKD3-5 and CKD5D. ACE activity was decreased in CKD3-5 with hypertension or dyslipidemia 
as compared to non-hypertensive (p=0.001) or without dyslipidemia (p=0.004) (Table 3). We 
found a significant indirect correlation between circulating ACE activity, age (p=0.033) and 
glycosylated hemoglobin (p=0.019) in CONT. 
ACE activity was increased in CONT and CKD3-5 in ARBs therapy as compared to non-treated 
patients. As expected, subjects treated with ACEi had lower levels of ACE activity as compared 
to non-treated subjects in all groups. ACE activity was decreased in CKD3-5 and CKD5D 
treated with cholecalciferol as compared to non-treated (Table 3). 
By multiple regression analysis (Table 4), female gender and younger age were identified as 
independent predictors of circulating ACE activity in CONT and CKD3-5. Diabetes was also 
identified as an independent predictor of circulating ACE activity in CKD3-5. As well as in the 
bivariate analysis, ACEi therapy was inversely associated with ACE activity in all studied 
groups. Furthermore, cholecalciferol treatment was found as an independent predictor of ACE 
activity in CKD3-5 and CKD5D. ARBs therapy was identified as an independent predictor of 
circulating ACE activity in CONT. 
Discussion 
The present study demonstrates that circulating ACE2 and ACE activities may be measured in 
human EDTA plasma. This is the first study showing that circulating ACE2 activity is decreased 
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in CDK3-5 and dialysis patients without previous history of CV disease. In addition, we also 
showed that ACE2 correlates with the classical CV risk factors namely male gender, advanced 
age and diabetes in CKD3-5, and male gender and advanced age in CKD5D.  
ACE2 enzymatic activity has been widely studied in renal, heart and other tissues under 
physiological and pathological conditions [21, 22]. However, few studies have assessed human 
circulating ACE2 activity, and the majority of them measured ACE2 activity in serum or heparin 
blood samples [12, 13]. We previously measured circulating ACE2 activity in serum from KT and 
acute myocardial infarction patients [14, 17]. Initially, we were not able to measure ACE2 
activity in EDTA plasma samples. The chelating agent EDTA completely inhibits tissue ACE2 
and soluble secreted ACE2 from CHO cell media activity, by chelating the zinc ion required for 
the metalloprotease activity [22, 25]. Hence, we made an effort to measure ACE2 activity in 
EDTA plasma samples. We demonstrated by adding zinc chloride, and subsequently avoiding 
the EDTA chelating effect that ACE2 and ACE activities could be measured.  
Roberts et al. [18] demonstrated that plasma ACE2 activity was decreased in dialysis patients. 
In those patients, male gender and diabetes were associated with increased ACE2, while RAS 
blockade did not affect circulating ACE2. However, in their study the sample size was small and 
healthy subjects used for comparison were not contemporaneous with CKD patients. Here, we 
present a study with larger sample size (n=2572) and contemporaneous studied groups. Of note 
that in our study patients had no history of CV disease. In agreement with Roberts et al., initially 
we found circulating ACE2 activity decreased in dialysis patients. As expected, measurement of 
circulating ACE2 pre and post-dialysis showed no differences (data not shown), demonstrating 
that the enzyme is not removed by dialysis. One surmises that the hemodialysis itself could not 
alter the levels of the ACE2 activity in plasma owing to its large molecular size [26]. In our study, 
dialysis patients were younger than CKD3-5 and control groups. When paired case-control 
studies were performed, the differences among the CKD groups were not observed, suggesting 
that the decrease in ACE2 within the dialysis patients may be ascribed to age. Within CKD5D, 
CKD3-5 and CONT, a significant difference in the level of circulating ACE2 activity was 
demonstrated between males and females. Our results confirm the work of others, who showed 
that circulating ACE2 is sex-dependent, with higher levels in males [16-18]. Data from animal 
models suggest that soluble ACE2 shedding is stimulated by the tumor necrosis factor-α 
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convertase ADAM17 [27-29]. It is possible that the increase of ACE2 in males may be related to 
the increase of ADAM17 shedding. Further studies focused in the ADAM17/ACE2 axis and 
gender differences are needed to confirm this premise.  
Many studies have associated circulating ACE2 activity with higher risk of CV disease. Epelman 
et al. [15] have previously demonstrated that circulating ACE2 activity is elevated in patients 
with diagnosis of heart failure. In recent studies from our group we showed that ACE2 activity is 
up-regulated in the acute phase of ST-elevation myocardial infarction and correlates with the 
infarct size [14]. Furthermore, KT patients with a previous history of ischemic heart disease 
presented increased ACE2 activity [17]. Soro-Paavonen et al. demonstrated that circulating 
ACE2 is increased in patients with diabetes and decreased eGFR or other vascular 
complications such as CV disease [16]. In concordance, in our study we demonstrated that 
ACE2 activity is also increased in diabetic CKD patients and it correlates with glycosylated 
hemoglobin. In mice with experimental diabetes, ACE2 activity is increased in the renal cortex 
and in the circulation, suggesting a potential mechanism to adapt to diabetes-associated AngII 
overactivity [21, 22]. As circulating ACE2 activity is increased starting at an early stage of 
diabetes and correlates with GFR, the measurement of ACE2 activity may become a new 
biomarker of CV disease in CKD.  
Circulating ACE activity is increased in CKD3-5 and CKD5D without previous history of CV 
disease. We have demonstrated that ACE activity correlates with the classical CV risk factors 
such as male, advanced age and diabetes in CKD3-5. As expected, ACEi therapy was inversely 
associated with ACE activity in all groups. In concordance with our results, some studies have 
found lower levels of circulating ACE in subjects with a history of hypertension [12] and higher 
levels in diabetic patients with renal complications [30]. However, other studies have not found 
relationship between circulating ACE and the classical CV risk factors [17, 31, 32]. We surmise 
that the incongruences observed between studies and populations may be ascribed to the effect 
of RAS blockade on circulating ACE. For ethical reasons, RAS blockade agents were not 
stopped for the study.  
In conclusion, this study shows that circulating ACE2 and ACE activities can be recovered and 
detected in human EDTA-plasma samples by adding zinc chloride. In addition, ACE2 activity 
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directly correlated with the classical CV risk factors such as male gender, diabetes and older 
age. These findings may have therapeutic implications for CV disease and help to delay the 
progression of CKD. Prospective studies with a short and long-term follow-up will help us to 
elucidate the ACE2 role as a biomarker in CKD. 
  
Page 38 of 51Nephrology Dialysis Transplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
14 
 
Acknowledgments: This work was made with funding from the projects ISCIII-FEDER. PI 
11/01549, and ISCIII-RETICS REDinREN RD12/0021/0024.The authors would like to thank 
Anna Faura and its team from Hospital del Mar and the NEFRONA team (Eva Castro, Virtudes 
María, Teresa Molí, Meritxell Soria) and the Biobank of RedInRen for their invaluable support. 
The NEFRONA study is funded by a research grant from AbbVie and the Spanish government 
RETIC (RD12/0021) and FIS PI13/01565. The NEFRONA study investigator group is composed 
by the following: Aladrén Regidor, Mª José. Hospital Comarcal Ernest Lluch (Calatayud); 
Almirall, Jaume; Ponz, Esther. Corporació Parc Taulí (Barcelona); Arteaga Coloma, Jesús. 
Hospital de Navarra (Pamplona); Bajo Rubio, Mª Auxiliadora, Hospital La Paz (Madrid); Belart 
Rodríguez, Montserrat. Sistemes Renals (Lleida); Bielsa-García. Sara, Hospital Obispo Polanco 
(Teruel); Bover Sanjuan, Jordi. Fundació Puigvert. IIB Sant Pau (Barcelona); Bronsoms Artero, 
Josep. Clínica Girona (Girona); Cabezuelo Romero, Juan B; Muray Cases, Salomé. Hospital 
Reina Sofía (Murcia); Calviño Varela, Jesús. Hospital Universitario Lugus Augusti (Lugo); Caro 
Acevedo, Pilar. Clínica Ruber (Madrid); Carreras Bassa, Jordi. Diaverum Baix Llobregat 
(Barcelona); Cases Amenós, Aleix; Massó Jiménez, Elisabet. Hospital Clínic (Barcelona); 
Castilla Pérez, Jesús. Hospital de la Defensa (Zaragoza); Cigarrán Guldris, Secundino; López 
Prieto, Saray. Hospital Da Costa (Lugo); Comas Mongay, Lourdes. Hospital General de Vic 
(Barcelona); Comerma, Isabel. Hospital General de Manresa (Barcelona); Compte Jové, Mª 
Teresa, Hospital Santa Creu Jesús (Tarragona); Cuberes Izquierdo, Marta. Hospital Reina 
Sofía (Navarra); de Álvaro, Fernando; Hevia Ojanguren, Covadonga. Hospital Infanta Sofía 
(Madrid); de Arriba de la Fuente, Gabriel. Hospital Universitario Guadalajara (Guadalajara); del 
Pino y Pino, Mª Dolores. Complejo Hospitalario Universitario Torrecardenas (Almería); Diaz-
Tejeiro Izquierdo, Rafael. Hospital Virgen de la Salud (Toledo); Dotori, Marta. USP Marbella 
(Málaga); Duarte, Verónica. Hospital de Terrassa (Barcelona); Estupiñan Torres, Sara. Hospital 
Universitario Canarias (Santa Cruz de Tenerife); Fernández Reyes, Mª José. Hospital de 
Segovia (Segovia); Fernández Rodríguez, Mª Loreto. Hospital Príncipe de Asturias (Madrid); 
Fernández, Guillermina. Clínica Santa Isabel (Sevilla); Galán Serrano, Antonio. Hospital 
General Universitario de Valencia (Valencia); García Cantón, Cesar. Hospital Universitario 
Insular de Gran Canaria (Las Palmas); García Herrera, Antonio L. Hospital Universitario Puerto 
Real (Cádiz); García Mena, Mercedes. Hospital San Juan de Dios (Zaragoza); Gil Sacaluga, 
Page 39 of 51 Nephrology Dialysis Transplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
15 
 
Luis; Aguilar, Maria. Hospital Virgen del Rocío (Sevilla); Górriz, José Luis. Hospital Universitario 
Doctor Peset (Valencia); Huarte Loza, Emma. Hospital San Pedro (Logroño); Lerma, José Luis. 
Hospital Universitario Salamanca (Salamanca); Liebana Cañada, Antonio. Hospital de Jaén 
(Jaén); Marín Álvarez, Jesús Pedro. Hospital San Pedro de Alcántara (Cáceres); Martín 
Alemany, Nàdia. Hospital Josep Trueta (Girona); Martín García, Jesús. Hospital Nuestra 
Señora de Sonsoles (Ávila); Martínez Castelao, Alberto. Hospital Universitari de Bellvitge 
(Barcelona); Martínez Villaescusa, María. Complejo Hospitalario Universitario de Albacete 
(Albacete); Martínez, Isabel. Hospital Galdakao (Bilbao); Moina Eguren, Iñigo. Hospital Basurto 
(Bilbao); Moreno Los Huertos, Silvia. Hospital Santa Bárbara (Soria); Mouzo Mirco, Ricardo. 
Hospital El Bierzo, Ponferrada (León); Munar Vila, Antonia. Hospital Universitari Son Espases 
(Palma de Mallorca); Muñoz Díaz, Ana Beatriz. Hospital Virgen del Consuelo (Valencia); 
Navarro González, Juan F. Hospital Universitario Nuestra Señora de Candelaria (Santa Cruz de 
Tenerife); Nieto, Javier; Carreño, Agustín. Hospital General Universitario de Ciudad Real 
(Ciudad Real); Novoa Fernández, Enrique. Complexo Hospitalario de Ourense (Ourense); Ortiz, 
Alberto; Fernandez, Beatriz. IIS-Fundación Jiménez Díaz (Madrid); Paraíso, Vicente. Hospital 
Universitario del Henares (Madrid); Pérez Fontán, Miguel. Complejo Hospitalario Universitario A 
Coruña (A Coruña); Peris Domingo, Ana. Hospital Francesc de Borja (Valencia); Piñera Haces, 
Celestino. Hospital Universitario Marqués de Vald cilla (Santander); Prados Garrido, Mª 
Dolores. Hospital Universitario San Cecilio (Granada); Prieto Velasco, Mario. Hospital de León 
(León); Puig Marí, Carmina. Hospital d'Igualada (Barcelona); Rivera Gorrín, Maite. Hospital 
Universitario Ramón y Cajal (Madrid); Rubio, Esther. Hospital Puerta del Hierro (Madrid); Ruiz, 
Pilar. Hospital Sant Joan Despí Moisès Broggi (Barcelona); Salgueira Lazo, Mercedes; 
Martínez Puerto, Ana Isabel. Hospital Virgen Macarena (Sevilla); Sánchez Tomero, José 
Antonio. Hospital Universitario de la Princesa (Madrid); Sánchez, José Emilio. Hospital 
Universitario Central de Asturias (Oviedo); Sans Lorman, Ramon. Hospital de Figueres 
(Girona); Saracho, Ramon. Hospital de Santiago (Vitoria); Sarrias, Maria; Prat, Oreto. Hospital 
Universitari Vall d’Hebron (Barcelona); Sousa, Fernando. Hospital Rio Carrión (Palencia); 
Toran, Daniel. Hospital General de Jerez (Cadiz); Tornero Molina, Fernando. Hospital de 
Sureste (Arganda del Rey); Usón Carrasco, José Javier. Hospital Virgen de la Luz (Cuenca); 
Valera Cortes, Ildefonso. Hospital Virgen de la Victoria (Málaga); Vilaprinyo del Perugia, Mª 
Page 40 of 51Nephrology Dialysis Transplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
16 
 
Merce. Institut Catala d’Urologia i Nefrologia (Barcelona); Virto Ruiz, Rafael C. Hospital San 
Jorge (Huesca). 
 
 
  
Page 41 of 51 Nephrology Dialysis Transplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
17 
 
References 
1. Moreso F, Calvo N, Pascual J, et al. Early statin use is an independent predictor of long-
term graft survival. NDT Plus 2010;3:ii26-ii31 
2. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, 
cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305 
3. Betriu A, Martinez-Alonso M, Arcidiacono MV, et al. Prevalence of subclinical 
atheromatosis and associated risk factors in chronic kidney disease: the NEFRONA study. 
Nephrol Dial Transplant 2014;29:1415-1422 
4. Velez JC. The importance of the intrarenal renin-angiotensin system. Nat Clin Pract 
Nephrol 2009;5:89-100 
5. Acevedo HR, Rojas MD, Arceo SD, et al. Effect of 6-nonadecyl salicylic acid and its 
methyl ester on the induction of micronuclei in polychromatic erythrocytes in mouse 
peripheral blood. Mutat Res 2006;609:43-46 
6. Patel SK, Velkoska E, Burrell LM. Emerging markers in cardiovascular disease: where 
does angiotensin-converting enzyme 2 fit in? Clin Exp Pharmacol Physiol 2013;40:551-559 
7. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related 
carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000;87:E1-9 
8. Santos RA, Simoes e Silva AC, Maric C, et al. Angiotensin-(1-7) is an endogenous ligand 
for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 2003;100:8258-8263 
9. Shiota A, Yamamoto K, Ohishi M, et al. Loss of ACE2 accelerates time-dependent 
glomerular and tubulointerstitial damage in streptozotocin-induced diabetic mice. Hypertens 
Res 2010;33:298-307 
10. Oudit GY, Herzenberg AM, Kassiri Z, et al. Loss of angiotensin-converting enzyme-2 
leads to the late development of angiotensin II-dependent glomerulosclerosis. Am J Pathol 
2006;168:1808-1820 
11. Soler MJ, Wysocki J, Ye M, et al. ACE2 inhibition worsens glomerular injury in 
association with increased ACE expression in streptozotocin-induced diabetic mice. Kidney Int 
2007;72:614-623 
12. Rice GI, Jones AL, Grant PJ, et al. Circulating activities of angiotensin-converting 
enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study. 
Hypertension 2006;48:914-920 
13. Lew RA, Warner FJ, Hanchapola I, et al. Angiotens n-converting enzyme 2 catalytic 
activity in human plasma is masked by an endogenous inhibitor. Exp Physiol 2008;93:685-693 
14. Ortiz-Perez JT, Riera M, Bosch X, et al. Role of circulating angiotensin converting 
enzyme 2 in left ventricular remodeling following myocardial infarction: a prospective 
controlled study. PLoS One 2013;8:e61695 
15. Epelman S, Tang WH, Chen SY, et al. Detection of soluble angiotensin-converting 
enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the 
renin-angiotensin-aldosterone system. J Am Coll Cardiol 2008;52:750-754 
16. Soro-Paavonen A, Gordin D, Forsblom C, et al. Circulating ACE2 activity is increased in 
patients with type 1 diabetes and vascular complications. J Hypertens 2012;30:375-383 
17. Soler MJ, Riera M, Crespo M, et al. Circulating angiotensin-converting enzyme 2 
activity in kidney transplantation: a longitudinal pilot study. Nephron Clin Pract 2012;121:c144-
150 
18. Roberts MA, Velkoska E, Ierino FL, et al. Angiotensin-converting enzyme 2 activity in 
patients with chronic kidney disease. Nephrol Dial Transplant 2013;28:2287-2294 
19. Junyent M, Martinez M, Borras M, et al. Predicting cardiovascular disease morbidity 
and mortality in chronic kidney disease in Spain. The rationale and design of NEFRONA: a 
prospective, multicenter, observational cohort study. BMC Nephrol 2010;11:14 
Page 42 of 51Nephrology Dialysis Transplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
18 
 
20. Junyent M, Martinez M, Borras M, et al. [Usefulness of imaging techniques and novel 
biomarkers in the prediction of cardiovascular risk in patients with chronic kidney disease in 
Spain: the NEFRONA project]. Nefrologia 2010;30:119-126 
21. Riera M, Marquez E, Clotet S, et al. Effect of insulin on ACE2 activity and kidney 
function in the non-obese diabetic mouse. PLoS One 2014;9:e84683 
22. Wysocki J, Ye M, Soler MJ, et al. ACE and ACE2 activity in diabetic mice. Diabetes 
2006;55:2132-2139 
23. Schwager SL, Carmona AK, Sturrock ED. A high-throughput fluorimetric assay for 
angiotensin I-converting enzyme. Nat Protoc 2006;1:1961-1964 
24. Arroyo D, Betriu A, Martinez-Alonso M, et al. Observational multicenter study to 
evaluate the prevalence and prognosis of subclinical atheromatosis in a Spanish chronic kidney 
disease cohort: baseline data from the NEFRONA study. BMC Nephrol 2014;15:168 
25. Tipnis SR, Hooper NM, Hyde R, et al. A human homolog of angiotensin-converting 
enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol 
Chem 2000;275:33238-33243 
26. Wysocki J, Batlle D. Reduced plasma ACE2 activity in dialysis patients: another piece in 
the conundrum of factors involved in hypertension and cardiovascular morbidity? Nephrol Dial 
Transplant 2013;28:2200-2202 
27. Xiao F, Zimpelmann J, Agaybi S, et al. Characterization of angiotensin-converting 
enzyme 2 ectodomain shedding from mouse proximal tubular cells. PLoS One 2014;9:e85958 
28. Salem ES, Grobe N, Elased KM. Insulin treatment attenuates renal ADAM17 and ACE2 
shedding in diabetic Akita mice. Am J Physiol Renal Physiol 2014;306:F629-639 
29. Lambert DW, Yarski M, Warner FJ, et al. Tumor necrosis factor-alpha convertase 
(ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory 
syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol 
Chem 2005;280:30113-30119 
30. Marre M, Bernadet P, Gallois Y, et al. Relationships between angiotensin I converting 
enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. 
Diabetes 1994;43:384-388 
31. Cambien F, Costerousse O, Tiret L, et al. Plasma level and gene polymorphism of 
angiotensin-converting enzyme in relation to myocardial infarction. Circulation 1994;90:669-
676 
32. Alhenc-Gelas F, Richard J, Courbon D, et al. Distribution of plasma angiotensin I-
converting enzyme levels in healthy men: relationship to environmental and hormonal 
parameters. J Lab Clin Med 1991;117:33-39 
 
 
 
Page 43 of 51 Nephrology Dialysis Transplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
19 
 
Tables  
Table 1. Clinical characteristics of study cohorts.  
  P-values 
  Total 
population CONT CKD3-5 CKD5D CONT vs CKD3-5 CONT vs CKD5D CKD3-5 vs CKD5D 
Age (years) 56.8±12.65 54.3±11.49 59.5±11.86 52.86±13.77 p<0.001 p=0.094 p<0.001 
Male/Female 1555/1017 347/272 1093/662 409/279 p=0.020 p=0.632 p=0.593 
Diabetes 584 (22.7%) 76 (12.3%) 506 (28.8%) 124 (18.0%) p<0.001 p=0.038 p<0.001 
Hypertension 2006 (78%) 248 (40.1%) 1588 (90.5%) 590 (85.8%) p<0.001 p<0.001 p=0.009 
Dyslipidemia 1491 (58%) 231 (37.3%) 1215 (69.2%) 363 (52.8%) p<0.001 p<0.001 p<0.001 
Smoking 512 (19.9%) 128 (20.7%) 337 (19.2%) 138 (20.1%) p=0.149 p=0.091 p=1 
Body weight (kg) 76.4±15.23 77.2±15.03 78.0±14.85 72.40±15.70 p=0.642 p<0.001 p<0.001 
Glycosylated 
hemoglobin (%) 5.9±1.19 5.7±1.04 6.3±1.30 5.51±1.07 p<0.001 p=0.218 p<0.001 
Glomerular Filtration 
Rate (ml/min/1.73m2) 48.3±29.81 89.5±17.66 32.6±13.86 - p<0.001 - - 
ACEi treatment 680 (26.4%) 64 (10.3%) 601 (34.2%) 130 (18.9%) p<0.001 p=0.001 p<0.001 
ARB treatment 1116 (43.4%) 145 (23.4%) 994 (56.6%) 219 (31.8%) p<0.001 p=0.004 p<0.001 
Insulin treatment 316 (12.3%) 11 (1.8%) 281 (16.0%) 219 (31.8%) p<0.001 p<0.001 p=0.400 
Continuous variables are expressed as means ± SD and categorical variables are represented by the 
number and the percentage of patients. CONT, control patients; CKD3-5, non-dialysis patients with chronic 
kidney disease stage 3-5; CKD5D, dialysis patients; ACEi, inhibitors of angiotensin converting enzyme; 
ARB, angiotensin II receptor blockers.  
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Table 2. Intraclass Correlation Coefficients and percentage of recovery for ACE2 and 
ACE activity between different sample conditions.  
 
  Intraclass Correlation Coefficient 
  (95% Confidence Interval) 
  ACE2 Activity ACE Activity 
EDTA-plasma ZnCl2 sample vs Serum 
sample 
0.95 0.90 
(0.91 - 0.97) (0.90 - 0.95) 
Serum sample vs Plasma-Heparin sample 
0.95 0.93 
(0.91 - 0.98) (0.86 - 0.97) 
EDTA-plasma ZnCl2 sample vs Plasma-
Heparin sample 
0.97 0.84 
(0.94 - 0.98) (0.68 - 0.92) 
 % Recovery 
EDTA-plasma  ZnCl2 sample vs Serum 
sample 
107% 89% 
EDTA-plasma ZnCl2 sample vs Plasma-
Heparin sample 
91% 83% 
 
  
Page 45 of 51 Nephrology Dialysis Transplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
21 
 
Table 3. Influence of different variables and treatments on circulating ACE2 and ACE activity in 
each studied group.  
  
Circulating ACE2 activity Circulating ACE activity 
(RFU/µl/h)±SEM (RFU/µl)±SEM 
  CLINICAL VARIABLES 
    CONT CKD3-5 CKD5D CONT CKD3-5 CKD5D 
Gender 
Male 61.4±2.26 50.6±1.53 45.6±2.45 3541.2±94.8 4032.8±71.8 4574.9±109.9 
Female 42.5±1.61* 36.7±1.47* 27.7±1.37* 4144.1±106.9* 4426.9±98.6* 4270.0±141.8 
Diabetes 
No 51.8±1.59 43.4±1.35 37.1±1.43 3766.5±75.4 4103.5±66.7 4459.7±97.2 
Yes 62.0±4.30* 50.3±1.97* 45.0±6.06 4127.7±230.3 4378.0±117.7 4431.1±196.3 
Hypertension No 47.2±1.30 43.2±2.87 36.7±4.05 3825.9±89.6 4669.2±189.6 14666.3±188.5 Yes 62.0±3.18* 45.6±1.20 38.8±1.76 3782.5±120.5 4130.8±61.2* 4418.1±96.8 
Dyslipidemia No 49.5±1.61 43.6±1.55 33.9±1.30 3806.3±90.0 4404.8±105.8 4369.9±118.1 Yes 59.0±2.97* 46.2±1.47 42.7±2.83* 3814.1±120.1 4080.2±69.8* 4531.4±127.0 
Smoking No 51.7±1.49 44.5±1.19 38.0±1.74 3817.8±80.7 4229.4±65.2 4414.2±94.4 Yes 57.8±4.40 49.4±2.96* 40.5±4.02 3775.8±159.7 3976.7±130.5 4599.4±212.3 
Plaques 
Absence 48.9±2.29 39.7±1.89 31.2±1.70 3995.0±106.0 4159.6±99.9 4310.2±157.8 
Presence 56.7±1.94* 48.0±1.38* 41.8±2.19* 3638.5±97.0* 4191.7±71.8 4518.1±104.4 
   TREATMENTS 
    CONT CKD3-5 CKD5D CONT CKD3-5 CKD5D 
ACEi  
No 52.5±1.59 46.2±1.48 38.9±1.92 3908.4±75.5 4993.8±70.3 4945.9±87.5 
Yes 57.4±4.33 44.0±1.65 37.2±2.38 2889.8±203.0* 2694.7±64.6* 2410.6±145.4* 
ARB 
No 49.7±1.27 43.7±1.49 37.7±2.17 3719.6±80.3 3729.7±85.2 4367.3±102.4 
Yes 64.2±4.89* 46.7±1.62 40.3±1.99* 4116.3±158.3* 4535.1±77.8* 4647.1±163.8 
Oral  
antidiabetic 
drugs 
No 51.9±1.51 44.2±1.19 38.6±1.64 3795.0±75.2 4165.4±61.9 4464.7±88.1 
Yes 63.1±4.89* 54.6±3.31* 35.1±5.86 3937.7±245.2 4307.7±175.2 3954.3±582.9 
Insulin 
No 52.9±1.5 44.7±1.26 37.3±1.49 3805.3±72.1 4112.8±61.6 4470.8±94.4 
Yes 59.6±11.85 48.9±2.17* 45.5±6.84 4087.1±848.3 4549.9±168.3 4356.9±227.5 
Cholecalciferol 
No 53.0±1.50 45.6±1.15 39.0±1.66 3805.0±72.0 4214.4±59.7 4492.7±88.3 
Yes 56.9±0.00 37.9±4.51 25.0±3.94* 6215.3±0.00 3211.4±229.2* 3250.6±438.7* 
CONT, control patients; CKD3-5, non-dialysis patients with chronic kidney disease stage 3-5; CKD5D, 
dialysis patients; ACEi, inhibitors of angiotensin converting enzyme; ARB, angiotensin II receptor blockers. 
*p<0.05 (No vs Yes, Male vs Female and Absence vs Presence) 
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Table 4. Multiple linear regression analysis of potential predictors of circulating ACE2 and ACE 
activities.  
PREDICTORS OF CIRCULATING ACE2 ACTIVITY 
  Standardized coefficient (β) p-value 
 a) CONT 
  Male 0.243 <0.001 
  Advanced age 0.148 <0.001 
b) CKD3-5 
  Male 0.224 <0.001 
  Advanced age 0.060 0.020 
  Diabetes 0.074 0.004 
c) CKD5D 
  Male 0.318 <0.001 
  Advanced age 0.119 0.003 
  ARB treatment 0.095 0.020 
  Cholecalciferol treatment -0.095 0.018 
PREDICTORS OF CIRCULATING ACE ACTIVITY 
  Standardized coefficient (β) p-value 
 a) CONT 
  Male -0.182 <0.001 
  Advanced age -0.087 0.035 
  ACEi treatment -0.152 <0.001 
  ARB treatment 0.124 0.003 
b) CKD3-5 
  Male -0.062 0.004 
  Advanced age -0.069 0.001 
  Diabetes 0.071 0.001 
  ACEi treatment -0.562 <0.001 
  Cholecalciferol treatment -0.074 0.001 
c) CKD5D 
  ACEi treatment -0.580 <0.001 
  Cholecalciferol treatment -0.087 0.012 
Data are expressed as regression coefficients and p values. Dependent variables: circulating ACE2 
activity, expressed in LnACE2 and circulating ACE activity, expressed in LnACE. 
CONT, control patients; CKD3-5, non-dialysis patients with chronic kidney disease stage 3-5; CKD5D, 
dialysis patients; ACEi, inhibitors of angiotensin converting enzyme; ARB, angiotensin II receptor blockers. 
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Legends to figures 
 
Figure 1. Circulating ACE2 (A) and ACE (B) enzymatic activity at increased 
concentrations of Zinc Chloride (ZnCl2) (C) Standard curve of recombinant human ACE2 
(rhACE2). (D) ACE2 activity in EDTA-plasma samples with the rhACE2 and ZnCl2. (A) 
ACE2 activity was assessed in 6 different plasma samples (1-6) using the following 
concentrations of ZnCl2: 0, 0.5, 1 and 3 mM. (B)ACE activity was assessed in 4 different plasma 
samples (A-D) using the following concentrations of ZnCl2: 0, 7.81, 15.63 and 31.25 mM. (C) 
ACE2 activity was linearly increased with increasing the rhACE2 concentrations. (D) ACE2 
activity was assessed in 4 EDTA-plasma samples with the following conditions: EDTA-plasma 
alone; EDTA-plasma adding ZnCl2 at a concentration of 0.5 mM; EDTA-plasma adding 1 ng of 
rhACE2; and EDTA-plasma adding both ZnCl2 at 0.5 mM and 1 ng of rhACE2. 
 
Figure 2. Circulating ACE2 activity between studied groups. (A) ACE2 activity was 
significantly decreased in CKD3-5 (grey bars) and CKD5D (white bars) patients as compared to 
CONT (black bars) (*p<0.001). CKD3-5 showed an increase in plasma ACE2 activity as 
compared to CKD5D ($p<0.001). When matching samples with an equal distribution of gender, 
diabetes, hypertension, dyslipidemia, smoking habits, weight and age (B), ACE2 activity was 
significantly decreased in CKD3-5 and CKD5D as compared to CONT but no differences were 
found between CKD3-5 and CKD5D (p=0.27). 
CONT, control patients; CKD3-5, non-dialysis patients with chronic kidney disease stage 3-5; 
CKD5D, dialysis  
 
Figure 3. Circulating ACE activity between studied groups. (A) ACE activity was increased 
in CKD3-5 (grey bars) (*p=0.035) and in CKD5D (white bars) (*<0.001) as compared to CONT 
(black bars). CKD5D showed an increase in plasma ACE activity as compared to CKD3-5 
($p=0.001). When assessing a paired case-control study (B), same results were obtained.  
CONT, control patients; CKD3-5, non-dialysis patients with chronic kidney disease stage 3-5; 
CKD5D, dialysis  
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Figure 1. Circulating ACE2 (A) and ACE (B) enzymatic activity at increased concentrations of Zinc Chloride 
(ZnCl2) (C) Standard curve of recombinant human ACE2 (rhACE2). (D) ACE2 activity in EDTA-plasma 
samples with the rhACE2 and ZnCl2. (A) ACE2 activity was assessed in 6 different plasma samples (1-6) 
using the following concentrations of ZnCl2: 0, 0.5, 1 and 3 mM. (B)ACE activity was assessed in 4 different 
plasma samples (A-D) using the following concentrations of ZnCl2: 0, 7.81, 15.63 and 31.25 mM. (C) ACE2 
activity was linearly increased with increasing the rhACE2 concentrations. (D) ACE2 activity was assessed in 
4 EDTA-plasma samples with the following conditions: EDTA-plasma alone; EDTA-plasma adding ZnCl2 at a 
concentration of 0.5 mM; EDTA-plasma adding 1 ng of rhACE2; and EDTA-plasma adding both ZnCl2 at 0.5 
mM and 1 ng of rhACE2.  
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Figure 2. Circulating ACE2 activity between studied groups. (A) ACE2 activity was significantly decreased in 
CKD3-5 (grey bars) and CKD5D (white bars) patients as compared to CONT (black bars) (*p<0.001). CKD3-
5 showed an increase in plasma ACE2 activity as compared to CKD5D ($p<0.001). When matching samples 
with an equal distribution of gender, diabetes, hypertension, dyslipidemia, smoking habits, weight and age 
(B), ACE2 activity was significantly decreased in CKD3-5 and CKD5D as compared to CONT but no 
differences were found between CKD3-5 and CKD5D (p=0.27).  
CONT, control patients; CKD3-5, non-dialysis patients with chronic kidney disease stage 3-5; CKD5D, 
dialysis  
 
11x6mm (300 x 300 DPI)  
 
 
Page 50 of 51Nephrology Dialysis Transplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Figure 3. Circulating ACE activity between studied groups. (A) ACE activity was increased in CKD3-5 (grey 
bars) (*p=0.035) and in CKD5D (white bars) (*<0.001) as compared to CONT (black bars). CKD5D showed 
an increase in plasma ACE activity as compared to CKD3-5 ($p=0.001). When assessing a paired case-
control study (B), same results were obtained.  
CONT, control patients; CKD3-5, non-dialysis patients with chronic kidney disease stage 3-5; CKD5D, 
dialysis  
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